In this study, we observed that among patients with AML 65 years old or older, who comprise the majority of all patients with AML, the prognostic impact of favorable karyotype, FLT3 mutations and NPM1 mutations on OS is not statistically significant. The gene discussed is NPM1; the disease is acute myeloid leukemia.